test e igf 1 lr3 ghrp cycle IGF-1 Research: Extended Half-Life GHRH-stimulated pituitary small extracellular vesicles

Public Health 13 , 1597910

Despite these advances and their significant therapeutic potential, the molecular mechanisms underlying the potent cytoprotective effects of BPC157 remain largely undefined, limiting its full clinical translation

Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

View Abstract Surgery for bilateral outflow tract obstruction in elastin arteriopathy

doi: 10.1016/j.celrep.2021.110146

Three monoclonal antibody drug candidates are also being developed, two of which (apitegromab and trevogrumab) are intended for use alongside marketed weight-loss drugs to preserve lean muscle mass during medicalised weight-loss